• head_banner_01

OEM/ODM Factory Levetiracetam Powder - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We are committed to providing easy,time-saving and money-saving one-stop purchasing service of consumer for Nirmatrelvir Intermediate Manufacturer, 3 3-Dimethylbutyraldehyde, Manganese Chloride, To supply prospects with superb equipment and providers, and constantly build new machine is our company's organization objectives. We look ahead for your cooperation.
OEM/ODM Factory Levetiracetam Powder - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex Detail:

Product Detail

Name  Desmopressin
CAS number  16679-58-6
Molecular formula  C46H64N14O12S2
Molecular weight  1069.22
EINECS Number  240-726-7
Specific rotation  D25 +85.5 ± 2° (calculated for the free peptide)
Density  1.56±0.1 g/cm3(Predicted)
RTECS No.  YW9000000
Storage conditions  Store at 0°C
Solubility  H2O:soluble20mg/mL, clear, colorless
Acidity coefficient  (pKa) 9.90±0.15 (Predicted)

Synonyms

MPR-TYR-PHE-GLN-ASN-CYS-PRO-D-ARG-GLY-NH2; MINIRIN; [DEAMINO1, DARG8] VASOPRESSIN; [DEAMINO-CYS1, D-ARG8]-VASOPRESSIN; DDAVP, HUMAN; DESMOPRESSIN; DESMOPRESSIN, HUMAN; DESAMINO-[D-ARG8] VASOPRESSIN

Indications

(1) Treatment of central diabetes insipidus. After the drug can reduce urinary excretion, reduce urinary frequency and reduce nocturia.

(2) Treatment of nocturnal enuresis (patients aged 5 years or older).

(3) Test the renal urine concentration function, and carry out the differential diagnosis of renal function.

(4) For hemophilia and other bleeding diseases, this product can shorten the bleeding time and prevent bleeding. It can reduce the amount of intraoperative blood loss and postoperative oozing; especially in conjunction with reasonably controlled blood pressure during surgery, it can reduce intraoperative bleeding from different mechanisms, and reduce postoperative oozing, which can play a better role in blood protection.

Treatment of diabetes insipidus

Diabetes insipidus is primarily a disorder of water metabolism characterized by excess urine output, polydipsia, hypoosmolarity, and hypernatremia. Partial or complete deficiency of vasopressin (central diabetes insipidus), or renal insufficiency of vasopressin (nephrogenic diabetes insipidus) can be onset. Clinically, diabetes insipidus is similar to primary polydipsia, a condition in which excessive fluid intake is caused by a malfunction of the regulatory mechanism or abnormal thirst. Contrary to primary polydipsia, the increase in water intake in patients with diabetes insipidus is a corresponding response to changes in osmotic pressure or blood volume.


Product detail pictures:

OEM/ODM Factory Levetiracetam Powder - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex detail pictures

OEM/ODM Factory Levetiracetam Powder - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex detail pictures


Related Product Guide:

We now have several exceptional workers customers good at marketing, QC, and working with types of troublesome trouble during the creation system for OEM/ODM Factory Levetiracetam Powder - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex , The product will supply to all over the world, such as: Ecuador, Milan, London, We welcome customers from all over the world come to discuss business. We supply high quality products, reasonable prices and good services. We hope to sincerely build business relationships with customers from at home and abroad, jointly striving for a resplendent tomorrow.
  • The company account manager has a wealth of industry knowledge and experience, he could provide appropriate program according our needs and speak English fluently.
    5 Stars By Irma from Dominica - 2017.08.18 11:04
    The factory can meet continuously developing economic and market needs, so that their products are widely recognized and trusted, and that's why we chose this company.
    5 Stars By Jean Ascher from Chile - 2017.09.28 18:29
    Write your message here and send it to us